X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs BIOCON - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB BIOCON DR. REDDYS LAB/
BIOCON
 
P/E (TTM) x 22.6 17.6 128.2% View Chart
P/BV x 3.1 2.8 110.9% View Chart
Dividend Yield % 0.8 0.4 184.0%  

Financials

 DR. REDDYS LAB   BIOCON
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
BIOCON
Mar-18
DR. REDDYS LAB/
BIOCON
5-Yr Chart
Click to enlarge
High Rs2,8751,188 242.0%   
Low Rs1,888305 619.0%   
Sales per share (Unadj.) Rs930.268.7 1,353.6%  
Earnings per share (Unadj.) Rs117.47.6 1,554.9%  
Cash flow per share (Unadj.) Rs185.814.0 1,329.7%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.80.1 626.9%  
Book value per share (Unadj.) Rs844.486.3 978.0%  
Shares outstanding (eoy) m166.07600.00 27.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.610.9 23.6%   
Avg P/E ratio x20.398.9 20.5%  
P/CF ratio (eoy) x12.853.4 24.0%  
Price / Book Value ratio x2.88.6 32.6%  
Dividend payout %17.013.2 128.6%   
Avg Mkt Cap Rs m395,496447,900 88.3%   
No. of employees `00022.06.1 357.2%   
Total wages/salary Rs m33,5629,311 360.5%   
Avg. sales/employee Rs Th7,032.86,705.8 104.9%   
Avg. wages/employee Rs Th1,527.91,514.2 100.9%   
Avg. net profit/employee Rs Th887.7736.9 120.5%   
INCOME DATA
Net Sales Rs m154,48241,234 374.6%  
Other income Rs m3,3752,062 163.7%   
Total revenues Rs m157,85743,296 364.6%   
Gross profit Rs m31,7828,291 383.3%  
Depreciation Rs m11,3483,851 294.7%   
Interest Rs m889615 144.6%   
Profit before tax Rs m22,9205,887 389.3%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,569 245.9%   
Profit after tax Rs m19,5004,531 430.4%  
Gross profit margin %20.620.1 102.3%  
Effective tax rate %16.826.7 63.2%   
Net profit margin %12.611.0 114.9%  
BALANCE SHEET DATA
Current assets Rs m111,10141,486 267.8%   
Current liabilities Rs m58,97321,413 275.4%   
Net working cap to sales %33.748.7 69.3%  
Current ratio x1.91.9 97.2%  
Inventory Days Days7964 124.1%  
Debtors Days Days9494 100.0%  
Net fixed assets Rs m101,24550,661 199.8%   
Share capital Rs m8303,000 27.7%   
"Free" reserves Rs m139,40648,808 285.6%   
Net worth Rs m140,23651,808 270.7%   
Long term debt Rs m22,00017,898 122.9%   
Total assets Rs m224,65699,897 224.9%  
Interest coverage x26.810.6 253.3%   
Debt to equity ratio x0.20.3 45.4%  
Sales to assets ratio x0.70.4 166.6%   
Return on assets %9.15.2 176.2%  
Return on equity %13.98.7 159.0%  
Return on capital %14.99.6 155.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67312,058 735.4%   
Fx outflow Rs m19,1047,348 260.0%   
Net fx Rs m69,5694,710 1,477.0%   
CASH FLOW
From Operations Rs m28,7046,621 433.5%  
From Investments Rs m-7,727-6,840 113.0%  
From Financial Activity Rs m-21,326-2,397 889.7%  
Net Cashflow Rs m-314-2,612 12.0%  

Share Holding

Indian Promoters % 25.5 40.4 63.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.4 8.4 64.3%  
FIIs % 35.3 10.7 329.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 19.9 76.9%  
Shareholders   75,885 109,995 69.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STRIDES PHARMA SCIENCE  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

GRANULES INDIA Plunges by 5%; BSE HEALTHCARE Index Down 1.7% (Market Updates)

Jul 19, 2019 | Updated on Jul 19, 2019

GRANULES INDIA share price has plunged by 5% and its current market price is Rs 94. The BSE HEALTHCARE is down by 1.7%. The top gainers in the BSE HEALTHCARE Index are ALKEM LABORATORIES (up 1.9%) and SANOFI INDIA (up 1.5%). The top losers are GRANULES INDIA (down 5.1%) and BIOCON (down 8.4%).

BIOCON Plunges by 6%; BSE HEALTHCARE Index Down 1.0% (Market Updates)

Jul 19, 2019 | Updated on Jul 19, 2019

BIOCON share price has plunged by 6% and its current market price is Rs 265. The BSE HEALTHCARE is down by 1.0%. The top gainers in the BSE HEALTHCARE Index are ALKEM LABORATORIES (up 2.1%) and SANOFI INDIA (up 1.5%). The top losers is BIOCON (down 5.8%).

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 19, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS